Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia. Here, CD5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.